The Gastrointestinal Tract Is a Major Source of Echinocandin Drug Resistance in a Murine Model of Candida glabrata Colonization and Systemic Dissemination
Open Access
- 1 December 2017
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 61 (12)
Abstract
Candida species are a part of the human microbiome and can cause systemic infection upon immune suppression. Candida glabrata infections are increasing and have greater rates of antifungal resistance than other species. Here, we present a C. glabrata gastrointestinal (GI) colonization model to explore whether colonized yeast exposed to caspofungin, an echinocandin antifungal, develop characteristic resistance mutations and, upon immunosuppression, breakthrough causing systemic infection. Daily therapeutic dosing (5 mg/kg of body weight) of caspofungin resulted in no reduction in fecal burdens, organ breakthrough rates similar to control groups, and resistance rates (0 to 10%) similar to those reported clinically. Treatment with 20 mg/kg caspofungin initially reduced burdens, but a rebound following 5 to 9 days of treatment was accompanied by high levels of resistance ( FKS1 / FKS2 mutants). Although breakthrough rates decreased in this group, the same FKS mutants were recovered from organs. In an attempt to negate drug tolerance that is critical for resistance development, we cotreated mice with daily caspofungin and the chitin synthase inhibitor nikkomycin Z. The largest reduction (3 log) in GI burdens was obtained within 3 to 5 days of 20 mg/kg caspofungin plus nikkomycin treatment. Yet, echinocandin resistance, characterized by a novel Fks1-L630R substitution, was identified following 5 to 7 days of treatment. Therapeutic caspofungin plus nikkomycin treatment left GI burdens unchanged but significantly reduced organ breakthrough rates (20%; P < 0.05). Single-dose pharmacokinetics demonstrated low levels of drug penetration into the GI lumen posttreatment with caspofungin. Overall, we show that C. glabrata echinocandin resistance can arise within the GI tract and that resistant mutants can readily disseminate upon immunosuppression.Keywords
Funding Information
- HHS | National Institutes of Health (AI109025)
- Arnold and Mabel Beckman Foundation (Arnold O. Beckman postdoctoral fellowship)
This publication has 44 references indexed in Scilit:
- Elevated Chitin Content Reduces the Susceptibility of Candida Species to CaspofunginAntimicrobial Agents and Chemotherapy, 2013
- Pharmacodynamics of Echinocandins against Candida glabrata: Requirement for Dosage Escalation To Achieve Maximal Antifungal Activity in Neutropenic HostsAntimicrobial Agents and Chemotherapy, 2011
- FKS Mutations and Elevated Echinocandin MIC Values among Candida glabrata Isolates from U.S. Population-Based SurveillanceAntimicrobial Agents and Chemotherapy, 2010
- In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida SpeciesAntimicrobial Agents and Chemotherapy, 2010
- Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β- d -Glucan Synthase: Implication for the Existing Susceptibility BreakpointAntimicrobial Agents and Chemotherapy, 2009
- Genomic polymorphism in the population of Candida glabrata: Gene copy-number variation and chromosomal translocationsFungal Genetics and Biology, 2009
- Formation of new chromosomes as a virulence mechanism in yeast Candida glabrataProceedings of the National Academy of Sciences of the United States of America, 2009
- Increases in SLT2 Expression and Chitin Content Are Associated with Incomplete Killing of Candida glabrata by CaspofunginAntimicrobial Agents and Chemotherapy, 2008
- Epidemiology of Invasive Candidiasis: a Persistent Public Health ProblemClinical Microbiology Reviews, 2007
- Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. IsolatesAntimicrobial Agents and Chemotherapy, 2005